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ABSTRACT 
Apoptosis (programmed cell death) is a basic physiological process, essential in the 
balance between life and death of cells of normal tissues in the body. Apoptosis can be 
considered as cellular “suicide” initiated by the cell itself when infected by a virus or 
transformed into a cancer cell. Cancer is a genetic disease and in cancer cells the 
molecules involved in initiation and execution of apoptosis are frequently lost or 
inactivated. Blockade of apoptosis is associated with resistance to conventional cancer 
drugs. The importance of intact apoptosis signaling pathways in leukemia and 
lymphoma was addressed in the current thesis. We found that apoptotic protease 
activating factor 1 (Apaf-1) is required for second mitochondria activator of caspases 
(Smac)-dependent potentiation of protein kinase inhibitor staurosporine- and 
proteasome inhibitor lactacystin-triggered apoptosis in chemoresistant Burkitt 
lymphoma cell lines Raji and DG-75. Furthermore, the importance of elevated levels of 
cellular inhibitor of apoptosis 2 (cIAP2), in these cells was examined in cellular 
extracts from Raji cells overexpressing cytosolic Apaf-1. Subsequently cytochrome c-
dependent caspase activation in Raji cells immunodepleted for cIAP2 was assessed. We 
found immunodepletion of cIAP2 to potentiate caspase activation only in Raji cells 
stably transfected with cytosolic Apaf-1. To further study the importance of Apaf-1 in 
response to proteasome inhibitors we used a T cell acute lymphoblastic leukemia (T-
ALL) cell line, Jurkat, stably transfected with shRNA against Apaf-1. The clinically 
relevant proteasome inhibitor bortezomib (Velcade®) failed to induce apoptosis in 
Jurkat cells without Apaf-1. The bortezomib-induced apoptosis was associated with 
induction of pro-apoptotic factor Noxa upstream of mitochondria. Moreover, we 
examined primary leukemic blasts from patients with T-ALL for Apaf-1 protein 
expression and responsiveness to bortezomib-induced apoptosis ex vivo. The Apaf-1 
protein expression varied amongst the different patient samples and although the 
sample number was low we noted the lowest increase in bortezomib-induced apoptosis 
in the patient sample completely deficient for Apaf-1. In order to elucidate the 
importance of other mediators of apoptosis, anti-apoptotic HS-associated protein X-1 
(HAX-1) was assessed at the protein and transcript level in malignant lymphomas. We 
thus determined the mRNA expression of HAX1 in two public transcriptomics 
databases. HAX-1 protein expression was assessed in a panel of 50 samples from 
patients with B lymphoma. We found that HAX-1 mRNA and protein was highly 
expressed in B lymphoma. Furthermore, we found a positive association with the 
proliferation marker Ki67 at the protein level in diffuse large B cell lymphoma 
(DLBCL) and Burkitt lymphoma samples, as well as an inverse correlation with Bcl-2 
at the protein and transcript level in follicular lymphoma. Finally, the actions of the 
specific inhibitor of chymotrypsin-like serine proteases, TPCK and the NF-κB inhibitor 
Bay-11 7082 were elucidated in chemoresistant cell lines Raji and DG-75. Both 
compounds induced caspase-independent apoptosis as well as a decrease in constitutive 
NF-κB activity. Moreover, we found that TPCK and Bay-11 7082 reduced protein and 
mRNA expression of the NF-κB target HAX-1, which may contribute to the 
sensitization to apoptosis. In summary, these studies contribute to our understanding of 
the importance of intact apoptotic signaling pathways in sensitivity to apoptosis 
induced by anti-cancer substances. Studies of different pro- and anti-apoptotic 
molecules may lead to the identification of novel targets for therapy. 
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1 INTRODUCTION 
1.1 APOPTOSIS 
1.1.1 Apoptosis through history and evolution 
The Greek word apoptosis can be translated into the “dropping off” of petals from a 
flower or leaves from a tree, and was presented by Wyllie, Kerr and Currie in 1972 in 
an attempt to rationalize the nomenclature concerning normally occurring cell death in 
mammalian cells. However, the first reports on naturally dying cells in development 
were described already in the mid-19
th
 century (Fadeel and Orrenius, 2005). The 
significant contribution of Kerr et al lies not only in coining the word apoptosis but 
they also provided a detailed morphological description of the phenomenon as well as 
recognized it as something not restricted to embryogenesis (Kerr et al., 1972). Since 
then the essential role for apoptosis not only in physiological tissue homeostasis but a 
central function in the immune system and in the killing of cancer cells has been 
extensively described. During the three following decades apoptosis or programmed 
cell death was established as a genetically regulated process that required ATP. 
 
Pioneering molecular genetic studies performed in Caenorhabditis elegans performed 
largely during the 1990’s provided the foundation to the identification of the main 
players of the apoptosis machinery in mammals. Furthermore these studies show that 
the cell death process is conserved throughout evolution. The discovery of the 
apoptosis program with cell death abnormal (CED)-3, CED-4, CED-9 and Egg laying 
defective (EGL)-1 genes during development in C. elegans (Yuan and Horvitz, 1992, 
Yuan et al., 1993, Hengartner and Horvitz, 1994, Conradt and Horvitz, 1998) rendered 
the Nobel prize in Physiology or Medicine in 2002. Studies in Drosophila 
melanogaster have further confirmed the existence of a conserved pathway of apoptosis 
(Meier and Vousden, 2007). 
 
1.1.2 Intrinsic and extrinsic apoptosis signaling 
Genetic and biochemical studies have identified two major pathways to programmed 
cell death that are largely independent; the extrinsic or the receptor-mediated pathway 
and the intrinsic or mitochondria-dependent pathway (Figure 1). The extrinsic pathway 
is activated upon binding of the designated ligand to a death receptor. This induces the 
recruitment of the adaptor molecule, a receptor-associated death domain and pro-
caspase-8/10, which results in the formation of the death-inducing signaling complex 
(DISC). DISC formation leads to the processing and activation of pro-caspase-8/10 and 
the initiation of a cascade of proteolytic activity within the cell. Cells in which caspase-
8 is strongly activated at the DISC, leading to the direct activation of caspase-3 and 
subsequent cell death, are classified as type I cells (Scaffidi et al., 1998). However, 
cells can also undergo apoptosis with reduced death receptor stimulation and no direct 
activation of pro-caspase-3 by caspase-8. Such cells are classified as type II cells, and 
require mitochondrial amplification of the initial death stimulus (Scaffidi et al., 1998). 
Thus, in the intrinsic or mitochondria-dependent apoptosis pathway, caspase-8 
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mediates the cleavage of Bid (a member of the Bcl-2 family) which is translocated to 
mitochondria, leading to a conformational change and oligomerization of the 
mitochondria-associated Bak and the cytosolic Bax forming pores in the outer 
mitochondrial membrane (Hsu et al., 1997, Griffiths et al., 1999). From the 
mitochondrial intermembrane space pro-apoptotic molecules such as the apoptosis 
inducing factor (AIF), second mitochondrial  activator of caspases (Smac/DIABLO), 
Omi/HtrA2, Endonuclease G (Endo G) and cytochrome c are released (Danial and 
Korsmeyer, 2004). Subsequently, cytochrome c induces an ATP driven conformational 
change of apoptotic protease-activating factor-1 (Apaf-1) forming a heptamer 
apoptosome complex (Fadeel et al., 2008). Within the apoptosome caspase-9 is 
activated by dimerization (Zou et al., 1999). Caspase-9, in turn, activates downstream 
effector caspases such as procaspase-3 and -7, resulting in apoptosis. Activation of 
caspase-3, -7 and -9 can be inhibited by members of the inhibitors of apoptosis proteins 
(IAP) family. In turn the IAPs are negatively regulated by binding of Smac (Figure 1). 
The intrinsic pathway is not only activated by cleavage of Bid but also directly by 
apoptotic stimuli such as cytotoxic compounds, DNA damage, growth factor 
deprivation etc. (Danial and Korsmeyer, 2004), summarized as cellular “stress” in 
Figure 1. 
 
 
Figure 1. Extrinsic and intrinsic apoptosis signaling. Consult text for details. DISC, 
death inducing signaling complex 
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1.1.3 Death receptors 
Tumor necrosis factor receptor 1 (TNFR1), Fas, TNF-related apoptosis-inducing-ligand 
(TRAIL) receptor are all cysteine-rich cell surface receptors related to the low-affinity 
nerve growth factor family. The extracellular region of these TNF receptor family 
members carries two to six repeats of cysteine-rich motifs. These receptors also share 
homology in their cytoplasmic domain which, in turn, is sufficient to trigger apoptosis 
when overexpressed alone, has been termed the death domain (Fulda and Debatin, 
2004). The TNFR1 also known as Death Receptor 1 (DR1) is involved in a number of 
physiological processes such as cytotoxicity, hepatocyte proliferation and in mediating 
inflammatory responses. Its designated ligand TNF efficiently activates TNR1-
dependent signaling activating downstream signaling cascades, e.g., activating NF-κB 
and c-Jun N-terminal kinase (JNK) (Schwenzer et al., 1999). Death receptor 2 (also 
termed CD95/APO-1/Fas) is the most studied and best characterized death receptor. 
Fas was identified in 1989 as a cell surface molecule involved in apoptosis (Trauth et 
al., 1989) and its ligand CD95L/FasL a few years later (Takahashi et al., 1994). Fas is 
highly expressed in activated lymphocytes and in a variety of lymphoid and non-
lymphoid tissues. FasL plays an important role in regulation of the immune system by 
triggering autocrine or paracrine cell death by activated T lymphocytes (Krammer, 
2000). Upon FasL binding to Fas, the receptor oligomerizes and the death domain-
containing adaptor molecule FADD is recruited together with pro-caspase-8, pro-
caspase-10, and the cellular FLICE inhibitory protein (FLIP) (Kischkel et al., 1995). 
DR4 and DR5 represent the tumor-related apoptosis inducing ligand receptor 1 and 2, 
respectively. The ligand, TRAIL, is a type-II transmembrane protein showing high 
homology to FasL (Wiley et al., 1995) and induces caspase-dependent apoptosis upon 
binding to the receptor in a similar manner to Fas/FasL (Krammer, 2000). Death 
ligands to all of the above mentioned death receptors have been demonstrated to 
interact with decoy receptors that lack the death domain and thus cannot form signaling 
complexes (Mahmood and Shukla, 2010). 
 
The role of death receptors and their ligands in cancer and cancer treatment has been 
extensively studied. When interrogating the in silico transcriptomics (IST) data base 
(Kilpinen et al., 2008) for the mRNA expression levels of Fas and FasL, elevated 
expression level is associated to hematological malignancies such as lymphoma and 
chronic lymphoblastic leukemia (Ottosson Wadlund, unpublished observation). In 
contrast, solid tumors such as breast cancer and head and neck cancer display increased 
transcript levels of TRAIL. Information on the expression of TRAIL receptor DR4 
(TNFRSF10A) is currently unavailable due to lack of probes on the assessed chip. 
However, relative mRNA expression of DR5 (TNFRSF10B) can be retrieved and is 
elevated in chronic lymphoblastic leukemia, mesothelioma, adrenal gland cancer and 
bladder cancer (Ottosson Wadlund, unpublished observation).  
 
1.1.4 Caspases 
At the center of the apoptotic machinery of mammalian cells a family of cystein 
proteases can be found. The name cystein-dependent aspartate-specific proteases 
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implies their enzymatic specificity, dominant for protein substrates containing Asp with 
the use of a cysteine side chain for catalyzing peptide bond cleavage. Members of the 
caspase family are conserved throughout evolution and the pro-apoptotic CED-3 gene 
was first described in C.elegans where it is absolutely necessary for apoptotic suicide. 
Caspases are essential for the maintenance of tissue homeostasis during development 
and especially during development of the central nervous system (CNS) and the heart. 
Knockout mice of caspase-3 and -9 die prenatally to a high extent and demonstrate 
severe enlargement and malformation of the brain (Kuida et al., 1996, Kuida et al., 
1998). Furthermore, isolated primary thymocytes from these knockout mice displays 
decreased sensitivity towards apoptotic stimuli (Kuida et al., 1996, Kuida et al., 1998, 
Woo et al., 1998). Targeted disruption of the CASP8 gene in mice produced a 
phenotype of in utero lethality and impaired heart muscle development (Varfolomeev 
et al., 1998). In ovaries of caspase-2 knockout mice an excess number germ cells were 
found, and caspase-2-deficient oocytes exhibited almost complete resistance to 
apoptosis. Moreover, B-cells from caspase-2-deficient mice were insensitive to 
granzyme B-induced apoptosis (Bergeron et al., 1998). Taken together, the importance 
of different caspases during development seems to be tissue specific, and the apoptotic 
response to different stimuli also reflects cell type specificity. 
 
To date, all 15 mammalian caspases described are related to the pro-inflammatory 
interleukin-1  converting enzyme (caspase-1) involved in cytokine processing.  
Caspases are thus involved in different biological processes, primarily inflammation 
(e.g., caspase-1, -4 and -5) and apoptosis where they are sub grouped as initiator/apical 
(e.g., caspase-2, -8, -9 and -10) or as executioner/effector (e.g., caspase-3, -6, and -7), 
but also keratinocyte differentiation (e.g., caspase-14) and suggested roles in 
proliferation and migration (Thornberry et al., 1992, Nicholson and Thornberry, 1997). 
Recently the 15
th
 member of the family of caspases was identified in pig, dog, and 
cattle, demonstrating pro-apoptotic activity (Eckhart et al., 2005). 
 
Caspases are abundantly expressed as inactive proforms or zymogens with regulatory 
N-terminal prodomains in the mammalian cell. All caspases comprise a regulatory N-
terminal domain as well as a catalytic domain with a large and a small subunit 
(Nicholson and Thornberry, 1997). Initially it was thought that all caspases where 
activated by proteolysis; however, recently is has become more and more evident that 
this is applicable first and foremost to the executioner caspases (caspase-3, -6, and -7). 
Initiator caspases (caspase-8, -9 and -10) require dimerization facilitated by recruitment 
to oligomeric activation platforms formed in response to apoptotic stimuli. This 
recruitment leads to a local increase in caspase concentration which in turn results in 
activity by proximity-induced dimerization (Muzio et al., 1998, Salvesen and Dixit, 
1999). The initiator caspases are specific to different activation platforms; the Death 
DISC activates caspase-8 and -10 via the caspase recruitment domain (CARD); the 
apoptosome activates caspase-9 via the death effector domain (DED); and the 
PIDDosome (PIDD, p53-induced protein with death domain) activates caspase-2 via 
the CARD (Chang et al., 2003). During the past decade increasing information on the 
dimerization and activation of inflammatory caspases has been reported. The 
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oligomeric platforms with affinity for the CARD prodomains are called 
inflammasomes and when dysregulated have been associated with inflammatory 
diseases such as Gout and Type 2 Diabetes (Schroder and Tschopp, 2010). Executioner 
(or short prodomain) caspases occur as inactive dimers that are activated upon cleavage 
of the catalytic domain (Salvesen and Dixit, 1999). 
 
Although the amino acid sequence of caspase substrates differs they are among the 
most specific of selective proteases and cleave their target protein after Asp residues. 
To date, all caspases described share one preferred cleavage site at the C-terminal of a 
four amino acid motif, X-X-X-D (X representing any amino acid and D representing 
Aspartic acid). Furthermore, among the different subsets of caspases high protein 
identity is found, resulting in similar substrate preferences. Inflammation-oriented 
caspases (caspase-1, -4, and -5) prefer the tetrapeptide sequence WEHD, initiator 
caspases (caspase-8, -9 and -10 with the exception of caspase-2) prefer the tetrapeptide 
sequence (I/L/V)EXD, and executioner caspases (caspase-3, -6, -7 and -2) prefer the 
tetrapeptide sequence DEXD (Denault and Salvesen, 2002). 
 
The activation of the proteolytic cascade of caspases is irreversible and thus requires 
strict regulation within the cell. Endogenous inhibitors of caspases are members of the 
Inhibitors of Apoptotic Proteases (IAP) family and will be discussed below. In addition 
to endogenous regulators the virally encoded cowpox virus CrmA and baculovirus p35 
proteins are able to suppress caspase-mediated host-responses (Denault and Salvesen, 
2002). 
 
Functional consequences of mutations and deletions of initiator and executioner 
caspase genes in tumorigenesis have been widely discussed in the literature. In a study 
by Teitz and colleagues it was demonstrated that low protein expression of caspase-8 
was the result of gene silencing of the CASP8 gene due to promoter methylation in 
childhood neuroblastoma (Teitz et al., 2000). Moreover, other mutations of CASP8 and 
CASP7 have been found in colorectal cancer as well as in head and neck cancer. 
Furthermore, decreased expression of caspase-3 on protein and transcript level has been 
associated to chemoresistance in breast adenocarcinoma (Olsson and Zhivotovsky, 
2011). Mutations or deletions of single caspases may not play a significant role in the 
development of a tumor cell phenotype. However, the central role of caspases in 
tumorigenesis may lie in the joint contribution of expression pattern changes of 
different caspases (Olsson and Zhivotovsky, 2011).  
 
 
1.1.5 Inhibitors of apoptosis (IAPs) 
The prototype IAP was first described in 1993 in a genetic screen of the baculoviral 
genome to identify regulators of host-cell viability during virus infection (Crook et al., 
1993). The human IAP family has since then grown and are today considered to consist 
of eight members, where the X-linked Inhibitor of Apoptotic Proteins (XIAP), is the 
best characterized member. The IAP family also includes cellular inhibitor of apoptosis 
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proteins 1 (c-IAP1), cellular inhibitor of apoptosis proteins 2 (c-IAP2) (Duckett et al., 
1996, Uren et al., 1996) and Survivin among others (Ambrosini et al., 1997). The IAPs 
contain one-three Baculovirus IAP Repeat (BIR), which signifies the IAP family, and 
an E3 ligase activity domain, the RING domain. The regions closely related to the 
BIR2 of XIAP specifically targets caspases-3 and -7, and regions closely related to the 
BIR3 specifically targets caspase-9. Moreover, the E3 ligase activity of the RING 
domain results in poly-ubiquitination of proteins targeting them for proteasomal 
degradation. However, ubiquitination does not always result in targeted degradation: in 
some situations, ubiquitination can modify the biological activity or subcellular 
localization of a protein. Consequently, the primary target of RING domain-mediated 
ubiquitination in XIAP is direct polyubiquitination of a lysine(s) outside the RING 
domain of XIAP (Yang et al., 2000). Furthermore, members of the IAP family are 
strictly regulated on a transcriptional level. For example, c-IAP2 and XIAP
 
are 
regulated by the pro-survival transcription factor nuclear factor of κ B (NF-κB). 
 
IAPs can also be regulated by pro-apoptotic factors and biochemical studies have led to 
the identification of the intermembrane space protein, second mitochondrial activator of 
caspases/direct IAP binding protein with low pI (Smac/DIABLO). On its release from 
mitochondria mature Smac/DIABLO binds XIAP, displacing caspases from XIAP. 
Smac/DIABLO can bind two distinct regions of XIAP. Residues 56–59 of 
Smac/DIABLO are homologous to the exposed amino-terminal motif that is used by 
caspase-9 to bind BIR3 of XIAP, and Smac/DIABLO has been found to bind to the 
same pocket in XIAP, thereby displacing caspase-9 from the complex (Srinivasula et 
al., 2001). 
 
XIAP protein has been shown to be highly expressed in Reed-Sternberg cells of 
Hodgkin lymphoma samples (Kashkar et al., 2003). Moreover, using the IST data base 
(Kilpinen et al., 2008) the relative mRNA expression of BIRC4 (XIAP) is increased 
primarily in hematological malignancies such as acute and chronic leukemia and 
myeloma. Moreover, solid tumors such as prostate and bladder cancer displays elevated 
transcript levels of BIRC4 (Ottosson Wadlund, unpublished observation).  
 
1.1.6 Apaf-1 and the apoptosome 
The (apoptotic protease activating factor-1) APAF1 gene is a human CED-4 homologue 
giving rise to at least three distinct splice forms (Shi, 2001). The APAF1 gene encodes 
a cytoplasmic protein containing several copies (12-13) of the WD-40 domain at the C-
terminus, a CED-4 homology ATPase domain (CED-4 like or NB-ARC) and a CARD 
at the N-terminus (Zou et al., 1997) (Figure 2). The protein was identified using 
cytosolic fractionation of HeLa cells in search of activators of caspase-3 and belongs to 
a family of nucleotide-binding and oligomerization domain (NOD) containing proteins 
(Zou et al., 1997). Most mammalian NOD proteins are involved in innate immune 
response signaling, Apaf-1 excluded, but they all oligomerize to execute their function 
as signal transducers (Schroder and Tschopp, 2010). Mice deficient for Apaf-1 die 
perinatal and the embryos displays morphological abnormalities of the brain and the 
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craniofacial compartment, similar to the ones of caspase-9 knockout mice. Moreover, 
primary embryonic fibroblasts from the Apaf-1 knockout mice examined for caspase-2, 
-3, -8 activity showed decreased activation in response to a variety of apoptotic stimuli 
(Cecconi et al., 1998, Yoshida et al., 1998). These studies show the fundamental role of 
the Apaf-1-dependent apoptosis pathway during CNS development. 
 
Cytochrome c, part of the respiratory chain and crucial for energy production in 
mitochondria, was identified as an important cofactor for the activation of caspase-3 by 
Soengas and colleagues and the cellular receptor for cytochrome c was later identified 
as Apaf-1 (Soengas et al., 2001). Cytochrome c and dATP were found to be essential 
cofactors for the formation of a ~ 700 kDa Apaf-1/caspase-9 complex, the apoptosome 
(Chou et al., 1998). Upon binding of cytochrome c Apaf-1 undergoes conformational 
changes promoting oligomerization and delocalization of the CARD domain. 
Oligomerization of Apaf-1 monomers arranges the CARD domains centrally in a wheel 
shaped structure (Figure 2). Crystal structure of murine Apaf-1 revealed how the 
monomer is kept in its autoinhibited conformation with ADP relying on an Arg residue 
in close proximity to the bound nucleotide (Reubold et al., 2011). The central hub of 
CARD domains provides a platform for procaspase-9 zymogen binding via the CARD 
domain of procaspase-9, resulting in subsequent activation of procaspase-9 (Chou et al., 
1998, Qin et al., 1999). Subsequently downstream effector caspases, such as caspase-3 
and -7 are activated resulting in cell death. 
 
 
Figure 2. (a) The Apaf-1 protein structure. (b) Apoptosome formation. Adapted from 
(Fadeel et al., 2008). 
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Apoptosis signaling downstream of mitochondria is regulated on multiple levels and 
the apoptosome is no exception. Positive and negative regulation of the apotosome by 
endogenous as well as exogenous factors was recently reviewed by Fadeel and co-
workers (Fadeel et al., 2008). Proteins directly interacting with Apaf-1 and negatively 
regulates apoptosome dependent signaling includes heat shock protein 70 and 90, while 
Nucling positively regulates apoptosome dependent signaling as reviewed by (Schafer 
and Kornbluth, 2006). Furthermore, mislocalization of the Apaf-1 protein, from the 
cytosol to other cellular compartments has been reported to negatively regulate 
apoptosome-dependent apoptosis in chemoresistant cell lines (Besse et al., 2004, Sun et 
al., 2005).  
 
As mentioned above Apaf-1 is subjected to transcriptional modification by differential 
splicing (Benedict et al., 2000). Epigenetic modification by hypermethylation of the 
APAF1 gene was reported in neuroblastoma recently (Grau et al., 2011) and 
hypermethylation of the APAF1 promoter has been observed in a variety of different 
types of cancer, including acute leukemia (Fadeel et al., 2008). The consequence of 
these epigenetic changes was demonstrated to be associated to chemoresistance and 
survival. Moverover, inhibition of histone deacetylase activity resulting in increased 
binding of E2F-1 and p53 to the APAF1 promoter increased the Apaf-1 protein 
expression and induced apoptosis in retinal cells has been reported (Wallace and Cotter, 
2009). 
 
1.1.7 The Bcl-2 protein family 
The BCL2 gene was originally discovered as an oncogenic gene at the chromosomal 
breakpoint in B-cell lymphoma carrying a t(14;18) chromosomal translocation 
(Tsujimoto et al., 1984). Subsequent studies found that Bcl-2 had potent anti-apoptotic 
activity and was capable of inhibiting apoptotic cell death induced by many different 
death signals (Adams and Cory, 1998). The BCL2 gene is essential for lymphoid 
development and a large number of proteins have been identified that belong to the 
BCL2 gene family. Bcl-2-related proteins, the BH3-only proteins, are recognized as key 
regulators of apoptosis and present both pro- and anti-apoptotic features. The anti-
apoptotic members of the Bcl-2 family (Bcl-1, Bcl-xL, Bcl-w, Mcl-1, A1, 
Boo/Diva/Bcl-2L10, Bcl-B and C.elegans CED-9) all contain three or four 
characteristic BH regions of homology (Bcl-2 Homology domains). Pro-apoptotic 
members of the Bcl-2 family are sub grouped according to their biochemical function 
and to their protein structure: containing two-three BH domains (Bax, Bak, Bcl-xS, Bok 
and Bcl-GL) or only one short BH3 domain (Bad, Bik, Blk, Bid, Hrk/DP5, Bim, Bmf, 
Noxa, Puma and C.elegans EGL-1) (Chonghaile and Letai, 2008). 
 
To avoid undesired activity the BH3-only proteins are tightly regulated, both 
transcriptionally and post-translationally. In C.elegans the EGL-1 gene is under 
transcriptional control by the repressor TRA-1A (Conradt and Horvitz, 1999). In 
mammals Noxa and Puma can both be regulated by p53 (Oda et al., 2000, Han et al., 
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2001), and the JNK-pathway has been shown to transcriptionally upregulate Bim in 
neurons (Harris and Johnson, 2001). Bim also undergo conformational changes upon 
apoptotic stimuli, releasing it from the dynein light chain of the microtubule and 
allowing it to translocate to mitochondria. (Puthalakath et al., 1999). Another example 
of post-translational modification of BH3-only proteins is the myristoylation of the 
truncated p15 tBid after cleavage by caspase-8, promoting its translocation to the 
mitochondria (Zha et al., 2000). Phosphorylation of Bad renders it inactive in a 
complex with 14-3-3ι scaffold proteins, preventing it to bind to pro-apoptotic Bcl-2 
family members (Zha et al., 1996). 
 
Transcript levels of BCL2 are elevated in human hematological malignancies according 
to the IST data base (Kilpinen et al., 2008). Moreover, protein expression of Bcl-2 has 
been demonstrated to be high in hematological malignancies (e.g., follicular 
lymphoma) (Reed, 2008). Several mechanisms have been suggested to account for this, 
including the chromosomal translocation t(14; 18) in patients with follicular lymphoma 
(Tsujimoto et al., 1984). Nonetheless, Bcl-2 overexpression has also been linked to 
gene amplification, hypermethylation of the BCL2 gene and decreased levels of pro-
apoptotic BH3-only proteins (Chonghaile and Letai, 2008). 
 
1.1.8 Caspase-independent cell death 
As described above apoptosis is normally orchestrated by the activation of caspases and 
subsequent chromatin condensation and DNA fragmentation. Nevertheless, cells have 
been shown to die without caspase activation and coincided with the release of 
mitochondrial factors such as AIF, Omi and Endo G (Kroemer and Martin, 2005). 
Upon treatment with substances like staurosporine AIF is cleaved from its membrane 
anchoring in the mitochondria. The 57 kDa AIF fragment can then be released to the 
cytosol upon mitochondrial membrane permeabilization. AIF subsequently translocates 
to the nucleus where it is involved in large-scale DNA fragmentation and cell death 
(Joza et al., 2001). Endo G is another mitochondrial factor that is released during cell 
death and translocates to the nucleus. It has been demonstrated to participate in DNA 
degradation in C.elegans (Parrish and Xue, 2003). Furthermore, the mitochondrial 
serine protease Omi/HtrA2 can mediate both caspase-dependent and caspase-
independent apoptosis by cleavage of IAPs, the anti-apoptotic protein HAX-1 and 
Ped/Pea-15 (an inhibitor of the DISC and of stress kinase (Kroemer and Martin, 2005). 
 
1.1.9 HS-1-associated protein X-1 (HAX-1) 
By using a yeast two-hybrid screen with the multifunctional hematopoietic cell-specific 
protein 1 (HS1) Suzuki and colleagues identified the HS1-associated protein 1 (HAX-
1) (Suzuki et al., 1997). HAX-1 is a 35-kDa protein that is associated with the cytosolic 
side of mitochondrial and endoplasmic reticulum (ER) membranes, but lacks a proper 
transmembrane domain (Jeyaraju et al., 2009). The HAX1 gene regulation is still 
elusive. However, the expression of HAX-1 has been shown to be induced by cytokines 
(Chao et al., 2008) and recently it was demonstrated that HAX-1 is under 
transcriptional control of NF-κB (Jitkaew et al., 2009). Moreover, HAX-1 can be 
 10 
subjected to post-transcriptional modifications and to date, eight human splice variants 
(Lees et al., 2008) and seven rat splice variants have been identified (Grzybowska et al., 
2006).  
 
HAX-1 has been shown to interact with a number of cellular and viral proteins as well 
as mRNA, and be involved in multiple signaling pathways and cellular processes. The 
overall expression of HAX-1 has displayed relatively high abundance among different 
tissues and this might reflect the miscellaneous roles of HAX-1 (Fadeel and 
Grzybowska, 2009). Numerous studies have implicated the role of HAX-1 in apoptosis 
and its functional association with apoptosis-regulating proteins and organelles. A 
clinically relevant example of the anti-apoptotic functions has been demonstrated in 
severe congenital neutropenia (Kostmann disease), where homozygous HAX1 
mutations were identified (Klein et al., 2007). Specific mutations of HAX1 were shown 
to be associated with neurological and neuropsychological abnormalities in Kostmann 
patients (Carlsson et al., 2008). Furthermore, HAX-1 have been implicated in B cell 
receptor (BCR)-mediated apoptosis, and in blocking of Bax-induced apoptosis as well 
as in inhibition of caspase-9 mediated apoptosis (Fadeel and Grzybowska, 2009). In 
addition, it was recently reported that the mitochondrial serine protease Omi/HtrA2 was 
able to activate autophagy by down regulation of the protein expression of HAX-1, 
which in turn regulates Beclin-1 (Li et al., 2010). Another important physiological 
function where the role of HAX-1 has been suggested is in the regulation of cell 
migration. HAX-1 has been demonstrated to interact with F-actin associated protein 
cortactin in a polycystic kidney disease model (Gallagher et al., 2000). Moreover, 
HAX-1 was able to bind the β6 subunit of V6 intergrins and thereby regulate clathrin-
mediated endocytosis in an oral squamous cell carcinoma model (Ramsay et al., 2007). 
HAX-1 also regulates neutrophil adhesion and motility (Cavnar et al., 2011). These 
studies, might suggest that HAX-1 is important for metastatic tumor progression. 
 
1.1.10 Additional apoptotic regulators 
Calpains are a family of calcium-dependent cysteine proteases consisting of the µ-
calpain or calpain-1 and the m-calpain or calpain-2 expressed in all tissues as well as 
number of tissue specific calpains. Calpain activity has been shown to be involved in a 
number of physiological processes such as cytoskeletal remodeling, cellular signaling, 
apoptosis and cell survival. The endogenous inhibitor calpastatin provides negative 
regulation in a calpain-calpastatin complex (Ono et al., 1998). The most common 
cellular compartment is the cytosol although calpains have recently been demonstrated 
to exist in mitochondria where it can cleave mitochondrial aspartate aminotransferase 
and AIF (Ozaki et al., 2007, Norberg et al., 2008). Mitochondrial µ-calpain has been 
suggested to be an initiator of AIF-induced cell death and m-calpain has been proposed 
to be involved in the release of truncated AIF to the cytosol (Ozaki et al., 2008, Ozaki 
et al., 2009). 
 
Granzymes are family of serine proteases released by cytotoxic members of the 
immune response, e.g., cytotoxic T cells (CTL) and NK cells in clearance of infected or 
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transformed cells. The cytotoxic granules of CTLs and NK cells contain a number of 
different granzymes as well as the pore-forming protein perforin. However, amongst 
granzymes the primary apoptosis mediator is granzyme B (GrB). Once in the target cell 
GrB is able to trigger several apoptotic pathways by proteolytic cleavage of death 
substrates. GrB has been demonstrated to activate both initiator and executioner 
caspases (Medema et al., 1997, Darmon et al., 1995) and to mediate direct cleavage of 
Bid and disruption of the Mcl-1/Bim complex (Heibein et al., 2000, Han et al., 2005).  
 
Lysosomes are organelles involved in degradation of cellular macromolecules and 
lysosomal hydrolases were long thought to induce only necrotic cell death. However, in 
1998 rat myocytes were shown to undergo cathepsin D-induced apoptosis in response 
to reactive oxygen species (Roberg and Öllinger, 1998). Cathepsin D is released after 
lysosomal membrane permeabilization triggered by a large number of different 
apoptotic stimuli such as reactive oxygen species. In addition, cathepsin D has been 
shown to be involved in TNFα-mediated apoptosis as well as in direct cleavage of Bid 
(Repnik et al., 2011).  
 
1.2 HEMATOLOGICAL MALIGNANCIES 
Even though the entity of leukemic disease has been known since the mid 1800 the 
causes are still not completely uncovered. Epidemiological studies have demonstrated 
that ionizing irradiation, chemical carcinogens, certain viral infections and genetic 
predisposition are important but not essential factors in the development the DNA 
changes prerequisite for different types of leukemia/lymphoma. Nevertheless, leukemic 
disease can be defined as a clonal expansion of a certain leukocyte at a specific state of 
differentiation, with an intact ability to proliferate and circumvent cell death (Lerner, 
2011). The characteristic DNA damages that results in the malignant features of 
hematological neoplasms are mainly the result of one or more changes in genes 
controlling functions such as the cell cycle (e.g., TP53, RB1 etc.), apoptosis (e.g., 
BCL2, MYC etc.), signal transduction (e.g., BCR/ABL, RASA1 etc.) (Mitelman et al., 
2007). The malignant phenotype can also be a result of viral infections by such as the 
Epstein Barr virus (EBV) and the human T-lymphotropic virus type I (HTLV-I). All 
hematological neoplasms are characterized by a blockage at a certain state of 
differentiation. In general acute leukemias and high grade proliferating lymphomas can 
be classified as neoplasms with changes in processes controlling proliferation, while 
chronic lymphoblastic leukemias and low grade non-Hodgkin lymphomas can be 
classified as neoplasms with changes in processes controlling survival and/or cell death 
(Lerner, 2011). Molecular genetic analyses of single proto oncogenes and tumor 
suppressor genes in hematological malignancies, have demonstrated that translocations 
occurs at an early state of the disease. On the other hand, point mutations and deletions 
of tumor suppressor genes such as TP53 or point mutations in oncogenes such as 
RASA1 occur at a much later state of the disease (Britschgi and Fey, 2009). 
 
 12 
1.2.1 The p53 family 
In 1979 a 53 kDa protein discovered was initially thought be an oncogene (Lane and 
Crawford, 1979), but has since then been reevaluated as one of the most important 
human tumor suppressor genes. The p53 protein family is a family of transcription 
factors including p53 and its homologues p63 and p73 (Graziano and De Laurenzi, 
2011). The TP53, TP63 and TP73 genes all encode several protein isoforms due to 
alternative promoters and differential splicing, which results in functional overlap to a 
certain extent. p63 has been demonstrated to be essential for maintenance and survival 
of epithelial stem cells (Graziano and De Laurenzi, 2011), while p73 is essential for 
survival and migration of neurons (Pozniak et al., 2000). 
 
The p53 knock-out mouse does not only demonstrate a high rate of spontaneous tumors 
but also display defects in the neural tube resulting in midbrain exencephaly and in 
utero death of the fetus (Donehower et al., 1992, Armstrong et al., 1995). Moreover, 
the TP53 gene is mutated in about 50% of all human tumors, and in about 10-15% of 
all leukemias (Mitani et al., 2007). TP53 status is associated with sensitivity towards 
anticancer drugs and radiotherapy (Lane, 2005). Upon cellular stress including DNA 
damage and oncogene activation p53 accumulates and triggers transcriptional 
activation of p53 target genes such as  p21, GADD45, Bax, Puma, Noxa, which in turn 
leads to cell cycle arrest, senescence and apoptosis (Landesman et al., 1997, McCurrach 
et al., 1997, Nakano and Vousden, 2001). Moreover, p53 has been shown to induce 
apoptosis of cancer cells by activation of caspase-2 via transcriptional upregulation of 
PIDD (Tinel and Tschopp, 2004). Furthermore p53 induces transcription of the MDM2 
gene, producing a protein that ubiquitinates p53, targeting it for proteasomal 
degradation (Lai et al., 2001). 
 
1.2.2 Malignant lymphomas 
Lymphomas are a group of malignant tumors typically presented as a solid tumor of 
lymphoid cells that most commonly originates from lymph nodes. Lymphoma can also 
involve other organs, e.g., the skin, brain bowl and bone, referred to as extranodal 
lymphoma. Every year 2000 new cases are presented in Sweden, and lymphoma is one 
of the ten most commonly occurring cancers (Bergman et al., 2010). There are about 20 
subgroups of lymphomas, and the six most common types are Diffuse Large B cell 
lymphomas (DLBCL), Chronic Lymphoblastic Leukemia (CLL), Follicular 
Lymphoma, Hodgkin Lymphoma, Immunocytoma, Mantle Cell Lymphoma are all of 
B-cell origin. Less common are for example Burkitt Lymphoma, Anaplastic 
Lymphoma, and Mucosa Associated Lymphoid Tissue Lymphoma (MALT) (Bergman 
et al., 2010). Survival of lymphoma patients is associated to the anatomical spread of 
the tumor which is classified by the Ann Arbor classification (Carbone et al., 1971). 
 
1.2.3 Burkitt lymphoma 
Burkitt lymphoma (BL) was first characterized as a lymphosarcoma by Irish surgeon 
Burkitt in 1958 (Burkitt, 1958). It can be described as a highly aggressive form of non-
Hodgkin B cell lymphoma most commonly occurring in young adults or children. BL 
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accounts for 40-50% of all childhood non-Hodgkin lymphoma. There are several 
different variants of BL including endemic, sporadic and immunodeficiency associated. 
Nevertheless, they all share the common characteristic hallmark of chromosomal 
translocation of the MYC oncogene (Yustein and Dang, 2007). BL is a malignancy of 
intermediate size B cells that infiltrate nodal or extranodal tissue in a diffuse pattern but 
depending on the variant can be presented differently. In endemic areas (i.e., equatorial 
Africa) there is a high tendency for the involvement of the facial bones in young 
children while in other geographic areas most patients present with abdominal tumors. 
Moreover the endemic variant is associated EBV and concomitant malaria infection 
(Wright, 1999).  
 
An unconditional feature of BL is the MYC translocation which, most commonly 
(approximately 85%) is the result of translocation of MYC from chromosome 8 to the 
IgH enhancer elements on chromosome 14 (t(8;14)) driving an inappropriate 
expression of c-myc. Although several translocations have been described in BL, 
including t(2;8) and t(8;22), they all result in deregulated expression of c-myc (Pelicci 
et al., 1986). At the same time the t(8;14) translocation may also be found in DLBCL 
and over the past decade the World Health Organization (WHO) has continuously 
updated the criteria for distinguishing BL from Burkitt-like lymphomas and DLBCL. 
With the introduction of transcriptional and genomic profiling using microarray 
techniques the molecular diagnosis of BL has improved and can be coupled to clinical 
outcome (Hummel et al., 2006). Initially BL was associated with poor outcome, but 
since the introduction of high intensity chemotherapy, the outcome has improved 
significantly. Currently, the initial therapeutic regime normally used is CHOP 
consisting of cyclophosphamide, vincristine, doxorubicin and prednisolone, but this can 
also be combined with high-dose methotrexate and etoposide etc. The CHOP regime 
corresponds to a typical therapeutic strategy in childhood malignancies and is used in 
treatment of both children and adults (Magrath et al., 1996). Recently the use of 
monoclonal antibodies as adjuvant in treatment of BL has become more frequent and 
resulted in favorable clinical outcomes. Among these anti-CD20 (i.e., rituximab) has 
been demonstrated to induce cytotoxicity by antibody-dependent as well as cell-
dependent mechanisms (Meinhardt et al., 2010). 
 
1.2.4 Myc 
The MYC proto-oncogene family (comprising c-myc, N-myc, and L-myc) ranks among 
the most studied group of genes in the literature. This family comprises of transcription 
factors of the basic region/helix-loop-helix zipper (bHLHZip) family that can 
heterodimerize with Max, another bHLHZip protein. It is believed that Myc exerts its 
main functions through gene regulation by recruiting transcriptional cofactors involved 
in modulation of RNA polymerase II function and of chromatin structure, including 
histone acetyl transferase complexes (Grandori et al., 2000). In normal cells, cellular 
processes including proliferation, growth, apoptosis, energy metabolism, and 
differentiation are under modulation by Myc proteins in response to external signals. 
The c-myc expression is induced by multiple mitogenic signaling pathways including 
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Wnt, Notch, STAT, receptor tyrosine kinases (RTKs), as well as hormone receptor 
pathways (Eilers and Eisenman, 2008). The Myc proteins are turned over at a very high 
rate via the ubiquitin/proteasome pathway involving at least three types of E3 ligases; 
SCF
Fbw7
, SCF
Skp2 
and HectH9 (von der Lehr et al., 2003, Adhikary et al., 2005).  
 
In response to extrinsic and intrinsic signals it has been suggested that Myc regulates 
10-15% of all genes and among its targets cell cycle regulatory genes, including 
cyclins, cyclin-dependent kinases (Cdk), Cdk inhibitors (CKI), E3 ubiquitin ligase 
components targeting CKIs and replication proteins can be found (Grandori et al., 
2000). Myc has also been demonstrated to regulate sensitivity towards apoptosis. In 
response to a variety of different stimuli such as ligation of death receptors, serum 
deprivation, hypoxia and cytotoxic drugs Myc has been shown to induce apoptosis 
(Eilers and Eisenman, 2008). Although the exact mechanisms by which Myc induces 
apoptosis remains to be elucidated, Myc induces the expression of the tumor suppressor 
protein p14Arf, which activates p53 by binding and sequestering the Mdm2 E3 ligase 
(Eischen et al., 1999). p53 in turn activates pro-apoptotic genes including BAX and 
BBC3 (Puma) as well as mediators of cell cycle arrest (e.g., p21CIP1). 
 
Activated MYC oncogenes contribute to the development of a wide variety of human 
cancer including leukemia, lymphoma and solid tumors, as a consequence of 
translocation, amplification point mutations or defects in upstream regulators. However 
deregulation of Myc also triggers intrinsic tumor suppressor mechanisms including 
activation of p53. The importance of apoptosis in Myc-induced tumor development has 
been well established. Thus, loss of pro-apoptotic genes including TP53, ARF, BAX and 
BIM or overexpression of anti-apoptotic genes such as BCL2L1 and BCL2 cooperates 
with MYC and accelerate tumorgenesis (Strasser et al., 1990). In contrast, the same 
group demonstrated that pro-apoptotic APAF1 and CASP9 was not essential for 
anticancer drug sensitivity of MYC-induced lymphomas and did not promote oncogene-
induced transformation of MEFs (Scott et al., 2004).   
 
1.2.5 EBV 
The Epstein–Barr virus (EBV) (named after British virologists Michael Anthony 
Epstein and Yvonne Murray Barr), also called human herpesvirus 4 (HHV-4), is a virus 
of the herpes family, which includes herpes simplex virus 1 and 2, and is one of the 
most common viruses in humans. It is best known as the cause of infectious 
mononucleosis, and a large part of the western world population is infected by the age 
of 20. It is also associated with particular forms of cancer, particularly Hodgkin's 
lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, and central nervous system 
lymphomas associated with human immunodeficiency virus (HIV). Furthermore, there 
is evidence that infection with the virus is associated with a higher risk of certain 
autoimmune diseases (James et al., 2001). Vaccines or specific therapy in treatment 
against EBV is currently not available. 
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The EBV penetrates cells, initially nasopharyngeal epithelial cells and B lymphocytes, 
by binding to the type 2 complement receptor CD21. At this stage, latent cycle genes 
produce a limited set of EBV proteins Epstein–Barr nuclear antigen (EBNA), latent 
membrane antigen (LMA), and terminal proteins (TPs). The virus reactivates 
occasionally, switching from latent to lytic cycle, with the production and expression of 
transactivating proteins, structural viral proteins, and envelope glycoproteins. EBV 
exerts a wide range of immune modulating effects, including inhibition of apoptosis, 
inhibition of the anti-EBV effects on interferon γ within B cells, and changes in the 
production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), 
interleukin (IL)-1, and IL-6. In addition, EBV produces a viral IL-10 that allow the 
virus to limit the host immune response (Kanegane et al., 1997). 
 
EBV is probably the most efficient transforming virus in culture and has been shown to 
be able to convert >50% of all target cells into continuously proliferating, latently 
infected lymphoblastoid cells (LCLs). Studies in LCLs revealed the expression of nine 
viral latent proteins and several non-coding RNAs that are under the transcriptional 
control of EBNA2 (Thorley-Lawson and Mann, 1985). Together, these cooperate to 
drive the newly infected resting cell to resemble an antigen-activated B lymphoblast. In 
combination with some of the latent genes (e.g., LMP1) EBNA2 constitutes the growth 
transcription program that contributes to the oncogenic actions of EBV (Thorley-
Lawson and Gross, 2004). 
 
1.2.6 Acute leukemia 
The word leukemia originates from Greek; leukos meaning white, and haima meaning 
blood and describes an abnormal clonal expansion of hematological precursors in the 
bone marrow rendering a leakage of these immature cells to the peripheral blood. The 
two main groups of acute leukemia are acute lymphoblastic leukemia (ALL) and acute 
myeloid leukemia (AML) and afflicts both adults and children all over the world. Acute 
leukemia is somewhat more common in men and the incidence increases with age. At 
the same time acute leukemia and brain tumors account for 50 % of all childhood 
cancer in the western world (Gaynon et al., 2010).  
 
Undoubtedly, the tools of molecular biology methods have increased the possibility of 
specifying the diagnosis for patients with acute leukemia. However, the foundation of 
all diagnostics in acute leukemia still relies of morphological examination of bone 
marrow smears. To further subgroup the acute leukemia the immunophenotype is 
determined by flow cytometry using a panel of antibodies. The antigens detected are 
markers for hematopoietic stem cells, B cells, T cells and myeloid cells etc. 
Cytogenetic evaluations contribute further to an adequate diagnosis and the most 
common translocations: t(4;11), t(6;11), t(9;11), t(11;19) and t(11;X) involves 
chromosome 11q23. These translocations all result in a number of oncogenic fusion 
proteins (Kagan, 1993). 
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Treatment outcome for children with acute myeloid leukemia (AML) and especially 
acute lymphoblastic leukemia (ALL) has improved substantially with the use of risk-
directed treatment and improved supportive care. The 5-year event-free survival rates 
for ALL now range between 76% and 86% in children receiving protocol-based 
therapy in the developed countries (Gaynon et al., 2010, Moricke et al., 2010). By using 
cytostatic drugs in combination with drugs against the side effects (anemia, bleeding 
and infection) the aim is to completely cure the patients. The anticancer drugs includes 
anti-metabolites (e.g., methotrexate), anthracyclins (e.g., daunorubicin), vinca alkaloids 
(e.g., vincristine) (Lerner, 2011) etc.  
 
 
1.3 CHEMOTHERAPY AND CHEMORESISTANCE 
Anticancer drugs represent one out of three entities (i.e., drugs, surgery and irradiation) 
of treatment strategy for patients suffering from malignancies and include a broad range 
of agents. Conventional anticancer therapy relies on three cornerstones: 1) the 
knowledge of tumor responsiveness to the specific drug, 2) an understanding of the 
mechanism(s) underlying the cytotoxic effects as well as mechanisms of resistance, and 
3) the pharmacokinetic features as well as side effects in normal tissue (Skipper et al., 
1970). Undoubtedly, the main objective of anticancer treatment is to cure the patient 
and anticancer therapy has for a long time, at least in models of leukemia, been 
associated the “fraction cell kill hypothesis” (Berenbaum, 1972). This hypothesis is 
based on the fundamental assumption of constant fractional kill per treatment cycle. On 
the other hand, it is unlikely to be valid of slow growing heterogeneous solid tumors. 
Moreover, the growing but still somewhat controversial (associated to confusion 
regarding the definition) field of cancer stem cells (CSC) is emerging with implications 
for modern anticancer treatment. By using substances targeting the rare subpopulation 
of cells (i.e., CSC) by which the entire tumor is sustained complete eradication of the 
tumor might be achieved (Gupta et al., 2009). However, work with B lymphoma in 
nonirradiated histocompatible recipient mice from Strasser and co-workers suggest that 
tumor growth is not necessarily driven by CSC (Kelly et al., 2007). 
 
Previous generations of today’s anti-cancer drugs were brought to clinical trials already 
in the 1940’s in the treatment of hematological malignancies. In using single agents 
such as nitrogen mustard, antifolates, corticosteroid and vinca alkaloids striking first 
responses were seen. Even though complete remission often was obtained relapse was 
common and always associated with resistance to therapy. Based on this the rationale 
combination therapy was introduced in treatment of human malignancies (Chabner, 
2006).  
 
For a favorable clinical outcome possible cross-resistance should be considered when 
formulating combination treatment therapies. Resistance to chemotherapy can be the 
result of inherent features of the tumor cells as well as the result of specific mutations. 
Examples of one unique mutation leading to cross-resistance are alterations in binding 
of inhibitors of enzymes that promote DNA strand breaks (e.g., topoisomerase II 
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inhibitors) in combinations of anthracyclins. In other respects, a single mutational 
change may lead to multidrug resistance as in the case of the ABCB1 gene, also referred 
to as the MDR-1 gene, which encodes the P-170 membrane glycoprotein. This 
evolutionary conserved membrane protein pump promotes the efflux of natural toxins 
such as vinca alkaloids, anthracyclins, taxenes, actinomycin D and epipodophyllotoxins 
(Kartner et al., 1983). The ABCB1 gene product belongs to a family of multi drug 
resistance proteins (MRPs) shown to be widely expressed in epithelial tumors (Ross 
and Doyle, 2004). Moreover, detoxification systems, including glutathione, have been 
demonstrated to be increased in tumor cells (Johansson et al., 2007). 
 
1.3.1 Conventional chemotherapy 
Virtually all chemotherapeutic drugs currently used induce apoptosis, when the 
apoptotic machinery of the cancer cells is intact (Fadeel and Orrenius, 2005). The first 
observation of apoptosis induction by antineoplastic drugs was reported more than 30 
years ago in seminal work from Kerr and co-workers (Searle et al., 1975). The effects 
of most conventional antineoplastic drugs rely on the concept that tumor cells are 
rapidly dividing and that the DNA integrity is compromised. By using combination 
therapy targeting both the fraction of slowly dividing G0 cells as well as the rapidly 
dividing cells in S phase, of for example solid tumor, effective response can be 
achieved. Furthermore, by the use of chemotherapy as neoadjuvant before surgical 
resection the bulk of tumors favorable clinical outcome can be accomplished. Some 
commonly used agents in anticancer treatment will be discussed below. 
 
One of the best characterized and most versatile chemotherapeutic agents used 
treatment of both solid tumors and leukemia are antifolate compounds. The anticancer 
functions of folate metabolism inhibitors (e.g., methotrexate) are a consequence of the 
substitution of an amino group for the hydroxyl at position 4 of the pteridine ring and 
thereby inhibiting DNA synthesis. This will activate p53 dependent transcription, 
inducing apoptosis via extrinsic (Friesen et al., 1999) as well as intrinsic signaling 
(Savion et al., 2009). A common mechanism of intrinsic or acquired resistance of 
resistance to methotrexate is identified as defective uptake (i.e., plasma membrane 
transport) (Rodenhuis et al., 1986). 
 
For more than 50 years guanine analogues (e.g., 6-mercaptopurine, 6-thioguanine and 
azathioprine) has been successfully used in treatment of childhood acute leukemia. 
More recently, cytidine analogues (e.g., arabinose nucleosides or Ara-C) has been 
incorporated in treatment regimens of AML, generally in combination with an 
anthracyclins. Ara-C induces tumor cell death by acting as an analogue of 
deoxycytidine, generating multiple effects on DNA synthesis, activating intrinsic 
apoptosis (Burnett et al., 2011). Resistance to Ara-C is coupled to mechanisms such as 
activity loss of deoxycytidine kinase, mutations in or over expressions of specific genes 
such as WT1, CEBPA, and the ratio of BCL2 to BAX  (Del Poeta et al., 2008) etc. 
Defects in apoptosome proteins, such as Apaf-1, are frequent in AML and treatment 
with 5-aza-2'-deoxycytidine, a specific inhibitor of DNA methylation, could restore 
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Apaf-1 expression and potentially increase efficiency of chemotherapeutic agents (Fu et 
al., 2003). 
 
Another compound used in treatment of myeloproliferative disease (i.e., chronic 
myelogenous leukemia) is hydroxyurea (HU). Originally synthesized in the late 1800’s 
it entered clinical trials in the 1960’s (Stearns et al., 1963). Hydroxyurea exert its 
cytotoxic actions by targeting ribonucleotide reductase (RR) causing DNA damage and 
activate the ATM- and Rad3-related (ATR) kinase. DNA damage induces upregulation 
of p53 and recent studies suggest that mitogen-activated protein kinase (MAPK) family 
and play an important role (Wei et al., 2011). 
 
Within the group of anthracyclin antibiotics daunorubicin and doxorubicin are among 
the most widely used anticancer agents in modern clinical practice. Discovered more 
than 40 years ago doxorubicin is primarily used in treatment of solid tumors including 
lymphoma (e.g., Hodgkin and non-Hodgkin lymphoma), while daunorubicin is used in 
treatment of acute leukemia (Dimarco et al., 1964). Anthracyclins show a high affinity 
for DNA, with a preference of dGdC-rich regions, and easily intercalates into the DNA 
helix (Chaires et al., 1990). The complete death inducing mechanisms of anthracyclins 
remain to be elucidated. However, doxorubicin was shown to result in caspase-
dependent ceramide-mediated apoptosis (Jaffrezou et al., 1996, Gamen et al., 2000).   
 
Originating from plant extracts used in traditional folk medicine, a number of 
semisynthetic derivatives with topoisomerase inhibitory effects have been produced. 
Under the brand name VePesid®, etoposide was approved for clinical use in 1984 
(Sinkule, 1984). Etoposide is used as second-line regimens or salvage therapies in non-
Hodgkin lymphomas including HIV-associated non-Hodgkin lymphomas (NHLs) 
(Sparano et al., 2004). The cytotoxic effect of topoisomerase II inhibitors is a result of 
stabilizing DNA cleavage complexes rather than preventing enzyme catalytic activity 
which will result in activation of the intrinsic apoptotic machinery. To this end, 
caspase-2 and Apaf-1 are suggested key players in etoposide-induced apoptosis (Lassus 
et al., 2002, Robertson et al., 2002, Sun et al., 2005).   
 
1.3.2 Proteasome inhibitors 
As opposed to conventional anticancer therapy the key target of novel anticancer drugs 
are functions and/or processes uniquely essential to the tumor cells. Novel drugs 
comprise structures such as macromolecules (e.g., monoclonal antibodies) to small 
molecule compounds. Examples of selective, tailored therapy targets presently in the 
clinic are the epidermal growth factor receptor (EGFR) (cetuximab), the epidermal 
growth factor receptor-tyrosine kinase (gefitinib), the HER2/neu human epidermal 
growth factor (trastuzimab), the BCR/ABL tyrosine kinase enzyme, angiogenesis 
(bevacizumab), and the proteasome (bortezomib, which will be discussed below). 
Promising future therapeutic targets lies within activating an inhibited apoptosis 
program of tumor cells, for example the Bcl-2/Bcl-XL inhibitor ABT-737 (Oltersdorf 
et al., 2005) and the activator of mutated p53 PRIMA-1 (Bykov et al., 2002). 
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The 26S proteasome is a large, multicatalytic protease that degrades polyubiquitinated 
proteins into small peptides (Figure 3). The main structure composes of two 
subcomplexes: a 20S core particle with catalytic activity and a regulatory 19S 
regulatory particle. Proteolysis of short-lived or regulatory proteins, from all 
compartments (i.e., cytoplasm, nucleus ER etc.) of the cell is predominantly executed 
by the proteasome. Conjugation of ubiquitin, a highly evolutionarily conserved 76-
residue polypeptide, to the protein substrate is carried out via a three-step mechanism. 
Initially, the ubiquitin-activating enzyme E1 activates ubiquitin in an energy-dependent 
reaction. One of several E2 enzymes (ubiquitin-carrier proteins or ubiquitin-
conjugating enzymes) transfers the activated ubiquitin from E1, to the substrate that is 
specifically bound to a member of the ubiquitin-protein ligase family, E3. There are a 
number of different classes of E3 enzymes. For example the RING finger-containing 
E3s (e.g., XIAP) catalyze direct transfer of the activated ubiquitin to the E3-bound 
substrate. By adding activated ubiquitin moieties to internal Lys residues on the 
previously conjugated ubiquitin molecule, a polyubiquitin chain is synthesized. This 
polyubiquitin chain can then be recognized by the 26S proteasome (Glickman and 
Ciechanover, 2002).  
 
Figure 3. Inhibitory actions of proteasome inhibitor, bortezomib (Velcade®) on the 
human 26S proteasome. 
 
Bortezomib (Velcade®), a dipeptidyl boronic acid, is a highly selective inhibitor of the 
26S proteasome (Figure 3). It was approved in 2003 for treatment of relapsed refractory 
multiple myeloma (MM) and, more recently, for treatment of mantle cell lymphoma 
and newly diagnosed MM (Molineaux, 2011). It belongs to a second generation of 
proteasome inhibitors as opposed to Streptomyces metabolite lactacystin, a first 
generation proteasome inhibitor. Proteasome inhibitors constitute a reliable target for 
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cancer therapy due to the fact that the ubiquitin proteasome system is a highly 
conserved intracellular pathway. Moreover, the high abundance of proteasomes in 
certain types of cancers as well as in increased protein turnover in highly proliferating 
cells contributes to its efficacy (Kumatori et al., 1990). By inhibiting the proteasome 
these drugs affect essential cellular processes ranging from cell cycle regulation, 
proliferation to apoptosis. In the original publications by Anderson and colleagues on 
effects of bortezomib in multiple myeloma it was suggested that it induced cell death in 
NF-κB-dependent manner (Hideshima et al., 2001, Hideshima et al., 2002). However, 
NF-кB inhibition alone cannot explain the selective anti-cancer effect of bortezomib 
and has been demonstrated to act not only on cancer cells themselves, but also on 
stromal cells (Hideshima et al., 2001). Moreover, bortezomib has a chemosensitizing 
effect when administered together with other anti-cancer agents, an effect which may, 
in part, be due to the inhibition of NF-κB (Cusack et al., 2001, Russo et al., 2001, 
Bhalla et al., 2009). Recent studies have shown that bortezomib-induced apoptosis is 
dependent on factors involved in classical apoptotic signaling, such as the BH3-only 
protein Noxa (Smith et al., 2011). Although proteasome inhibitors comprise a 
promising group of anti-cancer drug reports of resistance are currently appearing in the 
literature. Mechanisms underlying bortezomib resistance are not fully understood but 
have been suggested to involve mutations of proteasomal subunits and Bcl-2 
upregulation (Franke et al., 2011, Smith et al., 2011). Moreover, most of the studies to 
date were conducted on MM cells, but studies in leukemic cells are needed, as 
bortezomib is under consideration for treatment of such malignancies (Vink et al., 
2006). 
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2 AIMS OF THE STUDY 
 
The overall aim of the current thesis project is to elucidate mechanisms of 
resistance to apoptosis induction in B lymphoma and acute lymphoblastic 
leukemia. The specific aims are to determine: 
 
 whether pharmacological and/or genetic manipulation of apoptotic 
protease-activating factor-1 (Apaf-1), second mitochondrial activator of 
caspases (Smac) and/or endogenous inhibitors of apoptosis (IAPs) can 
overcome chemoresistance in B lymphoma cells; 
 
 the importance of Apaf-1 in response to proteasome inhibitor versus death 
receptor-mediated apoptosis in T cell leukemic cells; 
 
 the expression of anti-apoptotic factor HS1-associated protein X1 (HAX-
1) at the protein and transcript level in human B lymphomas; 
 
 the responsiveness of chemoresistant B lymphoma cells to induction of 
NF-κB inhibition-induced apoptosis and the potential role of HAX-1 in 
apoptosis in B lymphoma cells. 
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3 MATERIALS AND METHODS 
Detailed description of the techniques, materials and methods used in our studies can be 
found in the publications and manuscripts included in this thesis. The sections below 
provide a summary of the methods. 
 
3.1 APOPTOSIS INDUCTION 
For apoptosis induction we used staurosporine and lactacystin (Paper I) (Sigma-
Aldrich, St Louis, MO), anti-Fas antibody clone CH11 (Paper II) (Medical and 
Biological Laboratories, Ltd, Nagoya, Japan), and TPCK and Bay-117082 (Paper IV) 
(Calbiochem, San Diego, CA). In addition etoposide (Bristol-Meyers, Stockholm, 
Sweden) was used as a control for the induction of intrinsic apoptosis (Paper IV).  
 
3.2 CELL CULTURE 
3.2.1 Cell lines 
Raji, the first continuous human cell line of hematopoietic origin, was established in 
1964 from a Nigerian Burkitt lymphoma patient by, and is positive for Epstein Barr 
virus (Pulvertaft, 1964). Raji cells lack a functional p53 gene as a result of point 
mutations on both alleles (Duthu et al., 1992) and are considered to be type I cells 
(Scaffidi et al., 1998). Cells were maintained in RPMI 1640 (Sigma) supplemented 
with 10% FBS, 1 mM L-glutamine and 100 U/mL penicillin/100 g/mL streptomycin 
in a humidified incubator at 37
o
C and 5% CO2. Every third or fourth day the cells were 
counted, using tryphan blue 1:1 dilution, and resuspended in fresh medium to a density 
of 0,4 x 10
6
 cells/ml, to keep them in a logarithmic growth phase (Paper I and IV). 
 
The DG-75 cell line was established in 1977 by Eva Klein, George Klein and co-
workers, and originated from a Burkitt lymphoma patient, negative for Epstein Barr 
virus (Ben-Bassat et al., 1977). Cells were maintained in RPMI 1640 supplemented 
with 10% FBS, 1 mM L-glutamine and 100 U/mL penicillin/100 g/mL streptomycin 
in a humified incubator at 37
o
C and 5% CO2. Every third or fourth day the cells were 
counted, using tryphan blue 1:1 dilution, and resuspended in fresh medium to a density 
of 0,2-0,25 x 10
6
 cells/ml, which keeps them in a logarithmic growth phase (Paper I and 
IV). 
 
The type II cell line Jurkat originates from human acute T cell leukemia and was 
established in 1977 (Schneider et al., 1977). The Jurkat cell line is considered to have a 
non-functional p53 gene (Mansilla et al., 2006). Cells were maintained in RPMI 1640 
supplemented with 10% FBS, 1 mM L-glutamine and 100 U/mL penicillin/100 g/mL 
streptomycin in a humified incubator at 37
o
C and 5% CO2. Every third or fourth day 
the cells were counted, using tryphan blue 1:1 dilution, and resuspended in fresh 
medium to a density of 0,2-0,25 x 10
6
 cells/ml, which keeps them in a logarithmic 
growth phase (Paper II). 
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3.2.2 Primary leukemic blasts 
Primary leukemia blasts were obtained from children with acute leukemia at the 
Karolinska University Hospital. Informed consent
 
was obtained from each parent in 
accordance with the conditions
 
of the approval of the study by the local ethics 
committee (Stockholm,
 
Sweden). Mononuclear cells were isolated from bone marrow 
samples by
 
centrifugation on a Ficoll/Hypaque gradient (Lymphoprep, Oslo, Norway)
 
and cells were cryopreserved in liquid nitrogen in the presence
 
of 10% dimethyl 
sulfoxide. Upon thawing, lymphoblasts were
 
cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2% glutamine, 100 
units/ml penicillin and 100 µg/ml streptomycin (Life Technologies) as described 
previously (Laane et al., 2007) (Paper II). 
 
3.3 APOPTOSIS DETECTION 
3.3.1 Phosphatidyl serine exposure 
Plasma membrane exposure of phosphatidyl serine (PS) was determined by flow 
cytometric detection of the PS-binding protein annexin V using the annexin V-FITC 
apoptosis detection kit (Oncogene Research Products, Cambridge, MA, USA). Briefly, 
cells were harvested, washed and resuspended in HEPES buffer (10 mM Hepes, 150 
mM NaCl, 5 mM KCl, 1 mM MgCl ∙ 6H2O, 1.8 mM CaCl2 ∙ 6H2O) containing annexin 
V-FITC and propidium iodide (PI) before FACS analysis, as described previously 
(Karpova et al., 2006a) (Paper II). 
 
3.3.2 Caspase-3 activation 
Caspase-3 was fluorimetrically measured by cleavage of the fluorogenic substrate 
DEVD-AMC (Nicholson et al., 1995). Briefly, cells were harvested on ice and quickly 
frozen to -20
o
C. Fifty micro molar DEVD-AMC (in DMSO) was dissolved in the 
reaction buffer (100 mM HEPES, 10% sucrose and 0.1% 3-[(3-
Cholamidopropyl)+dimethylammonio]-1-propanesulfonate hydrate (CHAPS), pH 7,25) 
also containing 0.5% dithiothreitol (DTT), 0.01% Nonidet® P 40 (NP-40), and added 
to the cells. Product of the enzymatic reactions was measured in real time of enzyme-
catalyzed release of AMC using Tecan Infinite F200 plate reader (Tecan Group Ltd, 
Männedorf, Switzerland) operating with Magellan V6.5 software (Tecan Group Ltd, 
Männedorf, Switzerland) (Paper I, II and IV). 
 
3.3.3 Nuclear morphology changes 
Nuclear apoptosis was assessed as described previously (Karpova et al., 2006b). 
Briefly, cells were harvested and fixed in 2% paraformaldehyde. Cytospin preparations 
were stained with 1µg/mL Hoechst 33342. Apoptotic features (fragmented/condensed 
nuclei) of the cells were scored using fluorescence microscope (Paper I and IV). 
 
3.3.4 Hypodiploid DNA content 
Propidium iodide (PI) can be used to quantify the cellular DNA content and cellular 
fluorescence can then be measured using flow cytometry (Nicoletti et al., 1991). 
Briefly, cells were harvested, washed in PBS, pelleted and resuspended in 0.5 mL PBS 
 24 
based staining solution containing 50 g/mL PI, 0.1% Triton X-100, and 0.1% sodium 
citrate, and analyzed by FACS (Paper I, II and IV).  
 
3.3.5 Mitochondrial membrane potential  
Loss of mitochondrial membrane potential (MMP) was detected using 
tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes) (Jitkaew et al., 2009). 
Briefly, 20 min prior to harvesting the cells, 1 L (TMRE 25 nM) was added to the cell 
cultures. After washing the cells with PBS, HEPES buffer (10 mM Hepes, 150 mM 
NaCl, 5 mM KCl, 1 mM MgCl ∙ 6H2O, 1.8 mM CaCl2 ∙ 6H2O) containing TMRE was 
added and the samples were analyzed by FACS (Paper II and IV).  
 
3.4 OTHER IN VITRO METHODS 
3.4.1 Gel electrophoresis and western blot 
For total cell lysates, cells were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM 
NaCl, 10 % glycerol, 1 % NP-40, and 0.5 % deoxycholate). Protein concentration was 
measured using the BCA
TM
 Protein Assay Kit (Pierce Biotechnology Inc., Rockford, 
IL, USA). For cellular fractionation, 10
6
 cells were incubated on 5 min in KCl buffer 
(150 mM KCl, 1 mM MgCl  in 5 mM Tris pH 7.4) supplemented with 0.01 % 
digitonin, centrifuged, and supernatant (cytosolic fraction) and pellet (enriched 
mitochondrial fraction) was collected. Thirty microgram protein of each sample was 
loaded onto a sodium dodecyl sulfate (SDS)-gel, transferred onto polyvinylidene 
diflouride membranes and probed with the indicated antibodies. Proteins were 
visualized by enhanced chemiluminescence (ECL). The films were scanned, and 
densitometric analysis was performed using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA) (Papers I, II and IV). 
 
3.4.2 DNA damage assessment 
The Comet assay is utilized to monitor DNA damage (Kobayashi H, 1995). In brief, 
cells were harvested, washed with PBS, applied in 0.75 % Low Melting Point Agarose 
(LMPA) to pre-coated agarose glass slides, and lysed in lysis buffer (10 mM Tris, 2.5 
M NaCl, 100 mM EDTA). Glass slides were calibrated in electrophoresis buffer (10 N 
NaCl, 200 mM EDTA), run at 20 V and 150 mA for 20 min, neutralized with 
Neutralization Buffer (0.4 M Tris-HCl), stained with ethidium bromide and mounted on 
glass slides. At least 100 cells were counted for each sample at x10 or x40 
magnification using an inverted fluorescence microscope, and the % of cells with 
comet tails were determined (Paper II).  
 
3.4.3 Reactive oxygen species (ROS) measurements 
Production of superoxide was measured using dihydroethidium (DHE, Molecular 
Probes, Leiden, The Netherlands) as described elsewhere (Jitkaew et al., 2009). 
Oxidation of DHE by superoxide anion yields the fluorescent ethidium. Briefly, cells 
were incubated with 5 µM DHE in RPMI 1640 medium for 30 min at 37ºC. After 
resuspension in PBS, cells were submitted to FACS analysis using FACScan (Becton 
Dickinson) (Paper IV). 
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3.4.4 Immunofluorescent labeling of cells 
Localization of proteins was determined using immunocytochemistry and fluorescence 
microscopy. In brief, the cells were treated, fixed in 4% formaldehyde, permeabilized 
and blocked in 2% bovine serum albumin in 0.05% Triton X-100. The cells were 
incubated over night with primary antibody and with fluorescent probe-conjugated 
secondary antibody (Molecular Probes, Leiden, The Netherlands) for 1 h at room 
temperature, then stained with mounting medium containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA). The protein localization was evaluated using a 
Nikon ECLIPSE TE-2000-S fluorescence microscope (Nikon Corp.) equipped with a 
DS-5M digital camera operating with NIS-Elements software (Nikon Instruments, 
Badhoeverdorp, The Netherlands) (Paper IV). 
 
3.5 GENE EXPRESSION MICROARRAY ANALYSES AND 
BIOINFORMATICS 
Global gene expression profiling is a powerful strategy for improved understanding of 
the underlying pathogenesis and biology of human cancer (Quackenbush, 2006). 
Recent assembly of microarray data into databases provides means to assess the 
expression of single genes or groups of genes across multiple tissues and disease states. 
In paper II we utilized the Human Gene Expression Map, an online resource 
constructed from the integration of 5372 gene expression analyses of 369 different cell 
and tissue types, disease states and cell lines (Lukk et al., 2010). Statistical analyses of 
the three probes targeting the APAF1 gene on the Affymetrix HG-U133A were 
performed using one-way ANOVA with multiple group-wise comparisons to the global 
mean, and post-hoc tests were applied to identify selected comparisons and globally 
adjusted p-values. In paper III the In Silico Transcriptomics (IST) database containing 
data from 9,783 Affymetrix gene expression analyses of 43 normal tissues, 68 cancer 
types and 64 other diseases was used (Kilpinen et al., 2008).  
 
In paper IV total RNA was extracted from three separate experiments of unexposed and 
compound-exposed cells, respectively using Trizol reagent (Invitrogen, Carlsbad, CA) 
and the Qiagen RNeasy Mini columns (Qiagen, Chatsworth, CA) according to the 
manufacturers’ instructions. RNA concentration were determined using a Nanodrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), and RNA quality was 
determined using the RNA 6000 Nano LabChip kit and an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Purified RNA (RIN value ≥7) was amplified 
with the Illumina RNA TotalPrep Amplification kit (Ambion, Austin, TX) and the 
labeled cRNA was hybridized to HumanHT-12 v3 Expression BeadChips (Illumina 
Inc, San Diego, CA). Arrays were scanned with the Illumina BeadArray reader. The 
raw gene expression data were quantile-normalized and analyzed using the BioArray 
Software Environment (BASE) software (Vallon-Christersson et al., 2009) and R 
(www.r-project.org).  The Illumina probes were re-annotated using Re-annotation and 
Mapping for Oligonucleotide Array Technologies (ReMOAT) (Barbosa-Morais et al., 
2010), and for the ontology studies only probes with good or perfect quality were used.  
 
The differentially expressed transcripts from the compound-exposed cells relative to the 
un-exposed state were further mined by Gene Ontology (GO) categorization and 
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network analysis. The web-based functional annotation tool kit DAVID Bioinformatics 
Resources 6.7 (Database for Annotation, Visualization and Integrated Discovery, 
http://david.abcc.ncifcrf.gov/) was utilized to sort the transcripts based on GO 
categories. For each GO term the probability values were estimated based on the 
hypergeometric distribution by comparing the number of differentially expressed genes 
with the expected number of such genes as reference. The gene lists including 
significant differentially expressed genes were compared to a reference background 
containing genes representing probes with good or perfect quality according to 
Barbosa-Morais et al (Barbosa-Morais et al., 2010). Enriched categories encompassing 
at least 5% of the differentially expressed genes were selected from the analyses.  
 
Ingenuity Pathway Analysis (IPA) was applied to sort the differentially expressed 
genes into biological networks (http://www.ingenuity.com). Molecular networks for 
direct relationships were generated from data in the IPA knowledge base by uploading 
selected transcripts termed “focus genes” and corresponding expression values (“mean 
fold change”). Fisher’s exact test was applied for ranking and significance analysis of 
the focus genes in the network and a score of three (p<0.001) was set as a threshold, 
including association of the data to the most significant biological functions (termed 
“top functions”).  
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4 RESULTS 
 
4.1 PAPER I: SMAC-MEDIATED SENSITIZATION OF HUMAN B-
LYMPHOMA CELLS TO STAUROSPORINE- AND LACTACYSTIN-
TRIGGERED APOPTOSIS IS APOPTOSOME-DEPENDENT 
In this study the requirement of Apaf-1 for Smac-dependent potentiation of 
staurosporine- and lactacystin-triggered apoptosis was investigated. In addition, 
sensitization to Apaf-1-dependent caspase activation upon immunodepletion of 
inhibitor of caspase, cIAP2 was studied. Initially, we confirmed that Raji and DG-75 
display complete resistance to staurosporine (STS) and lactacystin compared to a panel 
of Burkitt lymphoma (BL) cells. IAPs are highly expressed in several types of human 
cancer and studies in Hodgkin lymphoma B cell lines have demonstrated high levels of 
XIAP as a mechanism of cytochrome c-dependent apoptosis resistance (Kashkar et al., 
2003, Wright and Duckett, 2005). We thus examined the protein expression of cIAP1, 
cIAP2 and XIAP in a panel of BL cells as well as apoptosis sensitive T-cell leukemic 
cell line Jurkat, and found that the expression of cIAP2 was elevated compared to 
Jurkat cells. To determine whether cIAP2 plays any role in the resistance to apoptosis 
in BL cells, cellular extracts from Raji cells immunodepleted for cIAP2 were examined 
for cytochrome c-dependent caspase activation, but remained refractory.  
 
Our group has previously shown that cytosolic expression of Apaf-1 plays a key role in 
cytostatic drug-induced apoptosis in BL cells (Sun et al., 2005). To further elucidate the 
mechanisms of apoptosis resistance in BL cells, cellular extracts from Raji cells 
overexpressing cytosolic Apaf-1 or mock transfected were immunodepleted for cIAP2. 
When examined for cytochrome c-dependent caspase activation we found 
immunodepletion of cIAP2 to potentiate caspase activation in Raji cells stably 
transfected with cytosolic Apaf-1. 
 
In a previous study from our group (Sun et al., 2005) as well as in this study we could 
conclude that the apoptosis resistant BL cells were able to release cytochrome c from 
mitochondria to the same extent as apoptosis sensitive Jurkat cells. Accordingly, the 
resistance to apoptosis induction in these cells involved other factors. Thus, we 
examined the release of pro-apoptotic factor Smac from mitochondria after treatment 
with STS and found the mitochondrial fraction of Smac to remain constant over time in 
Raji cells as opposed to Jurkat cells. To further elucidate the importance of Smac in the 
defective apoptosis signaling in Raji cells synthetic Smac-peptides were introduced to 
our system of cells overexpressing cytosolic Apaf-1 or not. Two different types of 
peptides were introduced; synthetic Smac-peptides conjugated with fluorescent probe 
FITC and FITC-conjugated control peptide expressing a scrambled amino acid 
sequence, or a non-fluorescently labeled synthetic Smac-peptide. Both types of Smac-
peptides were able to potentiate apoptosis in Raji cells overexpressing cytosolic Apaf-1 
in response to STS and lactacystin. 
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The importance of Apaf-1 in apoptosis signaling was further supported as the lipid-raft 
disrupting agent methyl-β-cyclodextrin, releasing Apaf-1 from its mislocalization in 
lipid rafts in the plasma membrane, could sensitize DG-75 cells to STS- and 
lactacystin-induced apoptosis. 
 
In summary we have provided evidence that cytosolic Apaf-1 expression is required for 
Smac-dependent potentiation of apoptosis of BL cells. Endogenous caspase inhibitor 
cIAP2 was demonstrated to serve as a modulator of sensitivity towards cytochrome c-
dependent caspase activation. 
 
4.2 PAPER II: REQUIREMENT OF APOPTOTIC PROTEASE-ACTIVATING 
FACTOR-1 FOR BORTEZOMIB-INDUCED APOPTOSIS BUT NOT 
FOR FAS-MEDIATED APOPTOSIS IN HUMAN LEUKEMIC CELLS 
In paper I (Sun et al., 2007) we studied the importance of Apaf-1 in microbial derived 
proteasome inhibitor lactacystin-induced apoptosis in BL cell lines. The proteasome 
inhibitor bortezomib has been approved for treatment of relapsed refractory multiple 
myeloma and, more recently, for treatment of mantle cell lymphoma. Clinical trials are 
underway to assess the efficacy of bortezomib in several other human malignancies 
including leukemia (Vink et al., 2006). Human leukemic cells express abnormally high 
levels of proteasomes compared with normal peripheral blood cells (Kumatori et al., 
1990) and leukemic cells are significantly more sensitive to proteasome inhibition than 
normal bone marrow progenitor cells or peripheral blood lymphocytes (Masdehors et 
al., 1999, Soligo et al., 2001). For this reason, we aimed and elucidated the importance 
of Apaf-1 for bortezomib-induced apoptosis using the T-cell leukemic Jurkat cell line. 
Treatment with bortezomib induced induction of the pro-apoptotic factor Noxa 
upstream of mitochondria, drop in MMP and release of cytochrome c from 
mitochondria in cells with or without Apaf-1. However, we only observed caspase-3-
like activity, PS-exposure, cells with hypodiploid DNA and PARP cleavage in cells 
with shRNA against Apaf-1 expression.  
 
For comparison, Jurkat cells with or without Apaf-1 expression were treated with 
agonistic anti-Fas antibodies to activate classical, death receptor-mediated apoptosis. 
Jurkat cells stably transfected with shRNA against Apaf-1 or with shRNA with mock 
sequence treated with agonistic anti-Fas antibody both induced apoptosis. 
Consequently, Fas-induced apoptosis in Jurkat (type II) appeared to be Apaf-1-
independent (and hence, cytochrome c-independent).  However, cell death may still 
very well depend on the release of mitochondrial factors, such as Smac and/or 
omi/HtrA2, as suggested previously (Shawgo et al., 2009).  
 
Interestingly, Jia et al. have previously reported that Apaf-1 deficiency is one 
mechanism underlying primary ALL blast resistance to cytochrome c-induced 
activation of caspase-3 (Jia et al., 2003b). For this reason, we examined Apaf-1 protein 
expression in leukemic blasts from pediatric patients with ALL, and assessed sensitivity 
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towards bortezomib-induced apoptosis. We found that the expression of Apaf-1 varied 
in a small panel of leukemic blasts from patients with ALL. Although sample number 
was low and assessing correlation of the responsiveness to bortezomib with Apaf-1 
expression difficult, we noted the lowest increase in apoptosis in response to 
bortezomib in the patient sample completely deficient for Apaf-1. 
 
Finally, in light of the fact that Apaf-1 expression appeared to be a key determinant of 
bortezomib-induced apoptosis in the Jurkat model, we explored the Human Gene 
Expression Map for the expression of Apaf-1 transcripts in a diverse range of human 
malignancies (Lukk et al., 2010). Assessment of the six leukemic subtypes relative to 
96 biological groups demonstrated consistently increased expression of Apaf-1 in acute 
lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, and 
precursor T lymphoblastic leukemia. Assessment of the 18 cell lines in the blood 
neoplasm cell line group, which also encompasses the Jurkat cell line, indicated similar 
Apaf-1 expression levels, with exception for the promyelocytic leukemic cell line 
HL60 that showed increased levels of Apaf-1. 
 
Taken together, these studies showed that Apaf-1 were required for the pro-apoptotic 
effects of bortezomib in the Jurkat T cell leukemic cell line. Our results also showed 
that bortezomib induced apoptosis by regulating pathways that are mechanistically 
different from those activated upon death receptor ligation. Furthermore, in silico 
analyses of public transcriptomics databases indicated elevated Apaf-1 expression in 
several hematological malignancies, including acute lymphoblastic and myeloid 
leukemia. We also noted variable Apaf-1 expression in a panel of samples from 
patients with acute lymphoblastic leukemia. Our results suggest that the expression of 
Apaf-1 may be predictive of the response to proteasome inhibition. 
 
4.3 PAPER III: HAX-1 EXPRESSION IN HUMAN B LYMPHOMA: 
ASSOCIATION WITH PROLIFERATION AND INVERSE 
CORRELATION WITH BCL-2 EXPRESSION  
In the third paper, we aimed to study the expression of HAX-1 in human B lymphoma 
on transcript and protein level. HAX-1 is a multifunctional protein with ubiquitous 
expression and evident roles in apoptosis and cell migration (Fadeel and Grzybowska, 
2009). However, HAX-1 expression has only been studied in a limited number of 
different cancer types and never in hematological malignancies. For this reason we 
determined the expression of HAX1 in two public transcriptomics database, the In 
Silico transcriptomics (IST) database, containing data from 9,783 Affymetrix gene 
expression analyses of 43 normal tissues, 68 cancer types and 64 other diseases, and the 
Human gene expression map derived from 5,372 samples of 369 different cell and 
tissue types including various disease states (Lukk et al., 2010, Kilpinen et al., 2008). In 
particular B-cell-related hematopoietic neoplasms malignancies, such as plasma-cell 
leukemia and B-cell lymphomas, showed a high expression of HAX1 using the IST data 
base. HAX1 was significantly overexpressed in hematological malignancies such as 
anaplastic large cell lymphoma when interrogating the Human gene expression map. 
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The Bcl-2 proto-oncogene was first described as a molecular feature of follicular B cell 
lymphoma (Yang and Korsmeyer, 1996), and for comparison we also examined the 
expression of BCL2 in the two public transcriptomics databases. 
 
To elucidate the protein expression of HAX-1 in B-cell derived hematological 
neoplasms a panel of 50 B lymphomas, including B-CLL, Immunocytoma, MALT 
lymphoma, Mantle cell lymphoma, Follicular lymphoma, DLBCL, Burkitt lymphoma 
and Hodgkin lymphoma was screened for expression of HAX-1. HAX-1 was shown to 
be highly expressed in DLBCL and Burkitt lymphoma both representing a lymphoma 
type with a high proliferative index measured by expression of Ki-67. Both types of 
lymphoma also displayed low levels of Bcl-2. The follicular lymphoma samples were 
selected upon mRNA expression of HAX1 retrieved from a previous publication by our 
group on microarray analysis on a cohort of follicular lymphoma (Björck et al., 2005). 
Three samples with high mRNA expression of HAX1 and three samples with low 
expression of HAX1 were selected from the cohort for the immunohistochemical 
staining. In follicular lymphomas that normally overexpress Bcl-2, we observed one 
samples with high expression of HAX-1 that were negative for Bcl-2. We then assessed 
the relative transcript levels of HAX1 and BCL2 using the complete dataset from a 
previous publication (Björck et al., 2005), and were able to demonstrate a negative 
correlation between HAX1 and BCL2 expression at the mRNA level. 
 
To conclude, our data showed varying expression of HAX-1 on protein and transcript 
level in different sub-groups of human B lymphoma. Elevated levels of HAX-1 could 
also be correlated to a high proliferative index at protein level and to low expression of 
Bcl-2 on protein and transcript level in follicular lymphoma. 
 
4.4 PAPER IV: Nɑ -TOSYL-L-PHENYLALANINE 
CHLOROMETHYLKETONE INDUCES CASPASE-INDEPENDENT 
APOPTOSIS IN CHEMORESISTANT BURKITT LYMPHOMA CELLS 
These studies were aimed at elucidating the mechanisms of chemoresistance in BL 
further using the specific inhibitor of chymotrypsin-like serine proteases, N
α
-tosyl-L-
phenylalanine chloromethylketone (TPCK) and the NF-κB inhibitor Bay-11 7082 
(Bay-11). The apoptosis-inducing ability by inhibition of NF-κB has been demonstrated 
in a variety of BL cell lines in the past decade (Zou et al., 2007, Klapproth et al., 2009, 
Nazari et al., 2011). Moreover, in a previous study by our group we reported that TPCK 
induces NF-κB-mediated caspase-dependent apoptosis in normal EBV-transformed B-
cells (Jitkaew et al., 2009). Apoptosis signal transduction downstream of mitochondria 
in the cell lines used in this study, Raji and DG-75 was previously shown to be 
impaired in response to etoposide (Sun et al., 2005). In contrast, when treating Raji and 
DG-75 cells with TPCK and Bay-11 we found that both compounds induced dose- and 
time dependent apoptosis in both cell lines. The apoptosis, measured by drop in MMP 
and percentage cells with hypodiploid DNA could not be blocked using the pan-
caspase inhibitor zVAD-fmk and no activation of caspase-3 was seen. 
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Based on the findings that BL cells expresses constitutive NF-κB binding activity in the 
nucleus, and have been suggested to be sensitive to NF-κB inhibition-induced cell 
death (Zou et al., 2007, Klapproth et al., 2009, Nazari et al., 2011) we hypothesized that 
the two compounds exerted their apoptotic actions in a similar fashion. For this reason 
we explored the effects on nuclear NF-κB expression after treatment with TPCK and 
Bay-11. Both treatments caused a decrease in the nuclear expression of NF-κB in Raji 
cells. Subsequently the cells were treated with TPCK or Bay-11 and the expression of 
NF-κB was assessed using fluorescence microscope evaluation. After 6 h the control 
cells in both cell lines displayed a clear nuclear localization. In contrast both treatments 
induced substantial cytosolic localization of NF-κB after both treatments.  
 
We previously published data demonstrating the decrease in the expression of HAX-1 
on protein and transcript level as a result of transcriptional regulation by NF-κB 
(Jitkaew et al., 2009). For this reason we examined the protein expression of HAX-1 in 
Raji and DG-75 cells after treatment with increasing doses of TPCK and Bay-11. Both 
treatments reduced the protein expression of HAX-1 in a dose-dependent fashion. 
However, at the highest doses of TPCK and Bay-11 not only the expression of HAX-1 
but also β-actin was reduced. Moreover, we assessed the effect of TPCK and Bay-
117082 on the expression of HAX1 splice variant I and II (Carlsson et al., 2008) using 
quantitative real-time PCR. The expression of splice variant II was reduced after 1 h 
while the expression of splice variant I was unaffected.  
 
In conclusion, we demonstrate the caspase-independent apoptosis-inducing effects of 
TPCK and Bay-11 on chemoresistant BL cells Raji and DG-75. Our data suggest that 
both compounds induce a decrease in constitutive NF-κB activity as well as reducing 
protein and mRNA expression of NF-κB target HAX-1, which may contribute to the 
sensitization to apoptosis. However, other effects of TPCK cannot be excluded. Future 
studies aimed at targeting silencing of HAX-1 expression may be informative. For 
comparison, B cells from patients with homozygos HAX1 mutations are more sensitive 
to TPCK induced apoptosis (Jitkaew et al., 2009).  
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5 DISCUSSION 
Apoptosis resistance contributes to carcinogenesis and chemoresistance, and acquired 
resistance towards apoptosis is a hallmark of most if not all types of cancer (Hanahan 
and Weinberg, 2011).  
 
One of the key players in mitochondria-mediated apoptosis, Apaf-1, has been shown to 
be involved in mechanisms of resistance to chemotherapeutic drugs in B lymphoma 
and leukemia models (Sun et al., 2005, Franklin and Robertson, 2007). A reduced 
cytosolic expression of Apaf-1 was the result of a mislocalization of Apaf-1 to lipid 
rafts in the plasma membrane and the mechanism of resistance in B lymphoma cells 
(Sun et al., 2005). The same mechanism could be applied for the resistance to protein 
kinase C inhibitor staurosporine (STS) - and proteasome inhibitor lactacystin-induced 
apoptosis in Burkitt lymphoma cells as well (Paper I). The effect of staurosporine and 
lactacystin could be significantly increased by the use of synthetic Smac peptides that 
in turn blocked the effect of IAPs in these cells. Furthermore, depletion of cIAP2 with 
monoclonal antibodies sensitized these cells to caspase activation in an Apaf-1-
dependent manner. Members of the IAP family are abundantly expressed in human 
tumors and one member, Survivin, has been commonly found in human tumor tissue 
but not in normal, terminally differentiated adult tissue (Deveraux and Reed, 1999). 
Moreover, interrogating the IST data base (Kilpinen et al., 2008) the relative mRNA 
expression of BIRC4 (XIAP) is increased primarily in hematological malignancies such 
as acute and chronic leukemia and myeloma, further supporting the potential for 
targeting IAPs in anti-cancer treatment. Possible prospects of synthetic Smac peptides 
in cancer treatment in combination with activators of extrinsic and intrinsic apoptosis 
signaling have been reported by other groups in xenograft models of malignant glioma 
(Fulda et al., 2002) and non-small cell lung cancer (Yang et al., 2003). The requirement 
of an intact apoptosome-signaling pathway in Smac-mediated apoptosis has been 
described in acute myeloid leukemia (AML) (Jia et al., 2003a). Upon treatment with 
synthetic Smac peptides proliferation was inhibited and the cells displayed cell cycle 
arrest, indicating that Smac peptides potentially could affect rapidly proliferating cells 
as well as indolent stem-like tumor cells. However, sufficient protein expression levels 
of Apaf-1 were required for efficient killing of the cells. An intact Apaf-1 protein 
expression in its adequate cellular compartment thus seems to be essential in apoptosis 
induction by various extrinsic and intrinsic stimuli. Hypermethylation of the Apaf-1 
promoter has been demonstrated in AML and ALL as well as several other different 
types of cancer (Fadeel et al., 2008). ALL samples completely deficient for Apaf-1 
were seen also in our study (Paper II); however, the mechanism for this was not 
examined. Consequently, upregulation of Apaf-1 protein expression by demethylation 
treatment might provide a potential strategy to sensitize leukemic cells to 
chemotherapy-induced apoptosis. Apaf-1 is a key player in responsiveness to apoptosis 
by not only classical chemotherapeutic agents but also to novel anticancer drugs such 
as proteasome inhibitors (Almond et al., 2001, Nikrad et al., 2005, Smith et al., 2011). 
The proteasome inhibitor bortezomib (Velcade®) is currently approved by the US Food 
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and Drug Administration (FDA) in treatment of relapsed refractory multiple myeloma 
and mantle cell myeloma. The rationale for extending the use of bortezomib to other 
hematological malignancies such as acute leukemia is not farfetched since the levels of 
proteasomes in human ALL and AML cells as well as CML cells is much greater than 
in normal peripheral blood cells (Vink et al., 2006). The combined information from 
our research as well as the research of other groups stipulates Apaf-1 as a determinant 
for responsiveness to apoptosis induced by cytostatic drugs as well as novel anticancer 
regimes in hematological malignancies. 
 
When classical caspase-dependent apoptosis signaling is perturbed cells may still 
succumb to apoptotic cell death. Caspase-independent mechanisms of cell death have 
been extensively described and involve different factors depending on the apoptosis 
inducing compound and cell type. Although the Bcl-2 homology of HAX-1 has been 
debated reports on the anti-apoptotic features of HAX-1 are manifold (Fadeel and 
Grzybowska, 2009). We suggest a potential redundancy of the two proteins as elevated 
levels of HAX-1 is correlated to a low expression of Bcl-2 in human B lymphoma 
(Paper III). The positive correlation with proliferation marker Ki67 might reflect the 
multi-functionality of HAX-1 and its suggested involvement in cancer cell migration 
(Ramsay et al., 2007). Additional mechanistic studies are needed in order to elucidate 
the role(s) of HAX-1 in the fate of tumor cells. However, determination of HAX-1 
expression on transcript and protein level might be of clinical significance in diagnosis 
and outcome of certain types of B lymphoma. Previous studies by members of our 
research group have indicated the role of HAX-1 in serine protease inhibitor, TPCK-
induced caspase-dependent cell death of normal EBV-transformed B cells (Jitkaew et 
al., 2009). Moreover, the expression of HAX-1 was suggested to be under 
transcriptional control of NF-κB. Indeed, this was supported in our study (Paper IV) as 
decreased nuclear activity of NF-κB was associated with a reduction in the expression 
of HAX-1 on protein and transcript level and coincided with induction of apoptosis of 
chemoresistant B lymphoma cell lines. Apoptosis induction by TPCK was caspase-
independent and did not involve cleavage of known substrates in caspase-dependent 
apoptosis signaling. This suggests that HAX-1 could be involved in apoptosis induction 
involving several different mechanisms with and without the involvement of caspases. 
The diversity of the functional attributes as well as diversity in cellular localization of 
HAX1 can most probably be explained by alternative splicing of the HAX1 gene. In a 
study by Trebinska and co-workers the expression of splice variant I and II was 
examined in panel of samples from patients with breast cancer. Notably, the variant 
I/variant II ratio was higher in normal tissue than in tumor tissue, and the relative 
overexpression ratio (tumor/normal) showed a higher overexpression of variant II in 
tumors than in normal tissue (Trebinska et al., 2010). This indicates that the expression 
of the different splice variants of HAX1 might exert different actions in normal versus 
tumor tissue. However, our findings do not exclude other possible perturbing 
characteristics of TPCK important in circumventing chemoresistance in Burkitt 
lymphoma cells. Altered redox status (i.e., oxidation) of cellular thiols has previously 
been demonstrated to trigger Bcl-2-independent drop in mitochondrial membrane 
potential and subsequent intrinsic apoptosis (Costantini et al., 2000). Due to the cellular 
localization of HAX-1 to membranes such as the ER-membrane and the nuclear 
membrane, but primarily to the mitochondrial membrane one might speculate that the 
 34 
latter localization is imperative for the anti-apoptotic functions of HAX-1. Moreover, 
some studies suggest that Burkitt lymphoma cells display limited uptake capacity for 
cystine, and are thus prone to oxidative stress-induced cell death (Banjac et al., 2008). 
TPCK-induced apoptosis in our study was associated with the production of reactive 
oxygen species (ROS). Nevertheless, the cell death could be inhibited by co-treatment 
with not only glutathione precursor N-acetyl-cystein but also by L- and D-cystein, 
suggesting direct post-translational modifications rather than ROS production as a 
mechanism for apoptosis. 
 
The studies in the present thesis are aimed at elucidating mechanisms of resistance to 
apoptosis induced by anticancer agents in B lymphoma and acute leukemia. For this 
purpose we have primarily used models of highly aggressive haematological 
malignancies commonly occurring in children; Burkitt lymphoma and acute 
lymphoblastic leukemia. The overall survival of patients suffering from these 
neoplasms has increased remarkably during the past three decades with the introduction 
of efficient treatment strategies (Magrath et al., 1996, Gaynon et al., 2010). These 
strategies include cycles of intensive therapy targeting rapidly diving cells, with 
limitless proliferative potential and decreased DNA integrity, affecting the bulk of the 
tumor cells. Slowly dividing or non-cycling tumor stem-like cells will not be affected 
and can possibly give rise to relapsed disease. Indolent lymphomas, such as follicular 
lymphoma, have demonstrated to be defective in their apoptotic signaling rather than in 
their inability to stop proliferating. In this context novel treatment strategies are needed 
for patients with inherent resistance to cytostatic drugs as well as for patients with 
chemoresistance-association relapsed disease. In this thesis we have utilized a 
combination of cell lines and primary patient-derived cells. Moreover, our studies on 
different factors involved in apoptosis resistance have been conducted using in vitro 
methods as well as in silico approaches. By focusing our research on reactivating the 
apoptotic program or inhibiting the anti-apoptotic machinery of tumor cells, such 
tailored treatment regimens might be achieved in the future.  
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6 CONCLUSIONS 
 
In summary, the main results obtained from this thesis suggest the following: 
 
 Apaf-1 is a determinant of responsiveness to conventional chemotherapeutic 
drugs, indicating possible biomarker function for clinical outcome in 
hematological malignancies  
 
 Apaf-1 is a determinant of responsiveness to novel anticancer drugs i.e.,  
proteasome inhibitors in hematological malignancies 
 
 HAX-1 expression is elevated in B lymphomas on transcript and protein level 
and show negative correlation to Bcl-2 expression and positive correlation to 
Ki67 expression  
 
 Caspase-independent apoptosis, in association with NF-κB inhibition and 
downregulation of HAX-1, provide means of circumventing chemoresistance in 
B lymphoma cells  
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